Trial reportMedical science monitor : international medical journal of experimental and clinical research2018
Effects of Kanglaite Injection on Serum miRNA-21 in Patients with Advanced Lung Cancer.
Trial report in Medical science monitor : international medical journal of experimental and clinical research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Chinese herbal injections combined with EGFR-TKIs for intervention of non-small cell lung cancer: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Progress in Mechanistic Research and the Use of Traditional Chinese Medicine in Treating Malignant Pleural Effusion.Cancer management and research · 2025Review
- Anti-tumor effect of coix seed based on the theory of medicinal and food homology.World journal of clinical oncology · 2023Review
- Modulation of AKT Pathway-Targeting miRNAs for Cancer Cell Treatment with Natural Products.International journal of molecular sciences · 2023Review
- An icaritin-loaded microemulsion based on coix oil for improved pharmacokinetics and enhanced antitumor efficacy.Drug delivery · 2022Article
- MicroRNA-155-5p promotes cell proliferation and invasion in lung squamous cell carcinoma through negative regulation of fibroblast growth factor 9 expression.Journal of thoracic disease · 2021Article
- miR-210-3p Promotes Lung Cancer Development and Progression by Modulating USF1 and PCGF3.OncoTargets and therapy · 2021Article
- Kanglaite Combined With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy for Stage III/IV Non-Small Cell Lung Cancer: A PRISMA-Compliant Meta-Analysis.Frontiers in pharmacology · 2021Article
- Article
- Coix Seed Oil Exerts an Anti-Triple-Negative Breast Cancer Effect by Disrupting miR-205/S1PR1 Axis.Frontiers in pharmacology · 2020Article
- Kanglaite Injection Combined with Chemotherapy versus Chemotherapy Alone for the Improvement of Clinical Efficacy and Immune Function in Patients with Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.Evidence-based complementary and alternative medicine : eCAM · 2020Review
- Formulation, Preparation and Evaluation of Nanostructured Lipid Carrier Containing Naringin and Coix Seed Oil for Anti-Tumor Application Based on "Unification of Medicines and Excipients".Drug design, development and therapy · 2020Article
- Upregulation of FTX Promotes Osteosarcoma Tumorigenesis by Increasing SOX4 Expression via miR-214-5p.OncoTargets and therapy · 2020Article
- Traditional Chinese Medicine Prolongs Progression-Free Survival and Enhances Therapeutic Effects in Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI)Treated Non-Small-Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Coix seed oil ameliorates cancer cachexia by counteracting muscle loss and fat lipolysis.BMC complementary and alternative medicine · 2019Article
- Efficacy of Paclitaxel Combined with Kanglaite Injection in Treatment of Bone Metastases of Lung Cancer.Iranian journal of public health · 2019Article
- Establishing a detection method for CCNY: a potentially significant clinical investigative marker in NSCLC patients.OncoTargets and therapy · 2019Article
- Epidermal Growth Factor Receptor (EGFR) Mutations and Anaplastic Lymphoma Kinase/Oncogene or C-Ros Oncogene 1 (ALK/ROS1) Fusions Inflict Non-Small Cell Lung Cancer (NSCLC) Female Patients Older Than 60 Years of Age.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- A Tf-modified tripterine-loaded coix seed oil microemulsion enhances anti-cervical cancer treatment.International journal of nanomedicine · 2018Article
- Yifei Sanjie Formula or Placebo With Anlotinib as Second-Line or Above Treatment for Metastatic Non-Small-Cell Lung Cancer: Study Protocol for a Double-Blind, Placebo-Controlled Randomized Pilot Study.Integrative cancer therapiesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Lung cancer is the most common type of cancer throughout the world, and the morbidity of lung cancer is continuously increasing. Patients with advanced lung cancer often cannot tolerate chemoradiotherapy. The decrease of the expression of miRNA-21 can be used as an indicator of the therapeutic effect of lung cancer. In this study, the effect of Kanglaite injection on serum miRNA-21 in patients with advanced lung cancer was investigated, providing reliable and important evidences. MATERIAL AND METHODS From March 2016 to March 2017, 120 patients with advanced lung cancer were examined; we collected detailed information and serum samples. The patients were treated by intravenous drip of Kanglaite, which was provided by Zhejiang Kanglaite Pharmaceutical Co., Ltd., China. We administered 200 ml intravenous drip once per day for a total of 21 days. Serum samples were collected from patients after treatments. In this study, 4 observation indexes were considered - KPS (Karnofsky performance score, KPS), body weight, adverse effects, and miRNA-21 level - evaluated before and after the Kanglaite treatment. RESULTS Among 120 patients with advanced lung cancer, the KPS of 75 patients (63.1%) was increased after the treatment, and body weight was increased by 55.9%. In addition, serum miRNA-21 level after the Kanglaite treatment was 2.45±0.15, which was significantly lower than before treatment (3.87±0.54), (P<0.05). CONCLUSIONS The effect of Kanglaite injection on serum miRNA-21 in patients with advanced lung cancer was shown to significantly reduce the expression of miRNA-21, providing objective evidence for the effect of Kanglaite injection in patients with advanced lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.